BioCentury | Feb 14, 2020
Product Development

AML’s growing options

For acute myelogenous leukemia patients, 2017 marked the end of a more than 40 year drought in which chemotherapy was the only treatment option. In the last three years, eight new AML therapies have come...
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

August decision dates for BMS, Seattle Genetics, Deciphera  A trio of cancer therapies have received Priority Review from FDA with August PDUFA dates. Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted a BLA for lisocabtagene maraleucel...
BioCentury | Feb 12, 2020
Product Development

Feb. 11 Product Development Quick Takes: J&J gets BARDA funding for COVID-19 vaccine; plus Novartis-Incyte, LogicBio and Elicio-Natera

BARDA to support Janssen COVID-19 vaccine R&D Johnson & Johnson (NYSE:JNJ) announced a collaboration with HHS that will speed development of a clinical COVID-19 (2019-nCoV) vaccine by its Janssen Pharmaceutical unit. The Biomedical Advanced Research...
BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

Exelixis believes newly released initial data from a Phase Ib trial cohort to treat prostate cancer could augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib plus Tecentriq...
BC Extra | Jan 31, 2020
Clinical News

AI strengthens grip on low hanging fruit with Exscientia, Dainippon Sumitomo trial start

Exscientia and Dainippon Sumitomo’s trial start for a compound accelerated through preclinical development via AI suggests the technology is starting to deliver on its first promise to drug developers: speeding up the chemistry they already...
BioCentury | Jan 29, 2020
Distillery Therapeutics

WWTR1-AXL-ABL2 axis inhibition for brain metastases in lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Blocking a signaling loop comprised of the transcription factor WWTR1 and the tyrosine kinases AXL and ABL2 could treat metastatic lung cancer. AXL and ABL2 signal between each other,...
BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BC Extra | Jan 24, 2020
Financial News

January fund-raising sets pace with $2.6B in follow-ons

A series of follow-ons pushed biotechs to raise about $1.5 billion this week, bringing January's total raise to about $2.6 billion via 16 follow-ons. The offerings have already outpaced last January, which saw $1.7 billion...
BC Extra | Jan 15, 2020
Financial News

Jan. 14 Financial Quick Takes: Schrödinger proposes NASDAQ IPO; plus Mirati, Blackstone, Orexia, Jasper, seqWell

Schrödinger seeking NASDAQ listing  Computational physics and drug discovery company Schrödinger Inc. proposed to raise up to $100 million in an IPO on NASDAQ. The company’s largest shareholders are the Bill and Melinda Gates Foundation...
BioCentury | Jan 13, 2020
Politics, Policy & Law

Supreme Court declines to clean up its IP mess

Over the last decade the U.S. Supreme Court has issued a series of decisions on the patentability of diagnostics that have befuddled lower courts, stifled investment, and led former U.S. Patent and Trademark Director David...
Items per page:
1 - 10 of 1322